期刊
EPIGENOMICS
卷 12, 期 16, 页码 1457-1476出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2020-0186
关键词
cancer immunotherapy; epigenetics; EZH2; immune editing
资金
- Higher Education Innovation Fund (HEIF-UK)
- Canadian Foundation for Translational Immunology
- CIHR [141635, 144159, 153081]
- TFRI program project [1062]
- MITACS [IT14958]
- National Cancer Institute [P50CA097186]
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immunoediting which ultimately leads to immune escape. The evolutionarily conserved histone modifier enhancer of zeste 2 (EZH2) is aberrantly overexpressed in a number of human cancers. Accumulating studies indicate that EZH2 is a main driver of cancer cells' immunoediting and mediate immune escape through downregulating immune recognition and activation, upregulating immune checkpoints and creating an immunosuppressive tumor microenvironment. In this review, we overviewed the roles of EZH2 in cancer immunoediting, the preclinical and clinical studies of current pharmacologic EZH2 inhibitors and the prospects for EZH2 inhibitor and immunotherapy combination for cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据